JP2015509368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509368A5 JP2015509368A5 JP2014558920A JP2014558920A JP2015509368A5 JP 2015509368 A5 JP2015509368 A5 JP 2015509368A5 JP 2014558920 A JP2014558920 A JP 2014558920A JP 2014558920 A JP2014558920 A JP 2014558920A JP 2015509368 A5 JP2015509368 A5 JP 2015509368A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603622P | 2012-02-27 | 2012-02-27 | |
| US61/603,622 | 2012-02-27 | ||
| PCT/US2013/027580 WO2013130381A1 (en) | 2012-02-27 | 2013-02-25 | Cx3cr1-binding polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509368A JP2015509368A (ja) | 2015-03-30 |
| JP2015509368A5 true JP2015509368A5 (https=) | 2015-05-07 |
| JP6101715B2 JP6101715B2 (ja) | 2017-03-22 |
Family
ID=47884535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558920A Active JP6101715B2 (ja) | 2012-02-27 | 2013-02-25 | Ｃｘ３ｃｒ１結合ポリペプチド |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US9035029B2 (https=) |
| EP (2) | EP2820046B1 (https=) |
| JP (1) | JP6101715B2 (https=) |
| KR (1) | KR102008136B1 (https=) |
| CN (3) | CN115925938A (https=) |
| AP (1) | AP2014007791A0 (https=) |
| AR (1) | AR090158A1 (https=) |
| AU (1) | AU2013226340B2 (https=) |
| CA (1) | CA2862182A1 (https=) |
| CL (1) | CL2014002072A1 (https=) |
| EA (1) | EA028183B1 (https=) |
| EC (1) | ECSP14020402A (https=) |
| GE (1) | GEP201706773B (https=) |
| IL (3) | IL291571B2 (https=) |
| IN (1) | IN2014DN05756A (https=) |
| MD (1) | MD4548C1 (https=) |
| MX (1) | MX349192B (https=) |
| NZ (1) | NZ627260A (https=) |
| PE (1) | PE20141859A1 (https=) |
| PH (2) | PH12014501912B1 (https=) |
| SG (1) | SG11201405283SA (https=) |
| TN (1) | TN2014000360A1 (https=) |
| TW (1) | TWI598361B (https=) |
| UA (1) | UA115781C2 (https=) |
| UY (1) | UY34644A (https=) |
| WO (1) | WO2013130381A1 (https=) |
| ZA (3) | ZA201405021B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9556273B2 (en) | 2010-03-29 | 2017-01-31 | Vib Vzw | Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages |
| US9101674B2 (en) | 2010-03-29 | 2015-08-11 | Vib Vzw | Targeting and in vivo imaging of tumor-associated macrophages |
| AU2013226340B2 (en) | 2012-02-27 | 2017-06-22 | Ablynx N.V. | CX3CR1-binding polypeptides |
| WO2015026884A1 (en) * | 2013-08-21 | 2015-02-26 | Boehringer Ingelheim International Gmbh | Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease |
| RU2609627C2 (ru) * | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |
| AU2016297249B2 (en) | 2015-07-23 | 2020-11-12 | Inhibrx Biosciences, Inc. | Multivalent and multispecific GITR-binding fusion proteins |
| WO2017123673A2 (en) | 2016-01-11 | 2017-07-20 | Inhibrx Lp | Multivalent and multispecific ox40-binding fusion proteins |
| KR20230041739A (ko) * | 2016-03-08 | 2023-03-24 | 매버릭 테라퓨틱스, 인크. | 유도성 결합 단백질 및 사용 방법 |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| US20200071408A1 (en) | 2016-11-29 | 2020-03-05 | National Center Of Neurology And Psychiatry | Prophylactic agent, onset-suppressing agent or therapeutic agent for progressive immune demyelinating diseases |
| US20190367623A1 (en) * | 2017-01-17 | 2019-12-05 | Yeda Research And Development Co. Ltd. | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| IL302613B2 (en) | 2017-09-08 | 2025-04-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| AR114552A1 (es) | 2018-08-13 | 2020-09-16 | Inhibrx Inc | Polipéptidos de unión a ox40 y sus usos |
| WO2020181140A1 (en) | 2019-03-05 | 2020-09-10 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| CN110675421B (zh) * | 2019-08-30 | 2022-03-15 | 电子科技大学 | 基于少量标注框的深度图像协同分割方法 |
| IL298695A (en) * | 2020-06-02 | 2023-02-01 | Childrens Medical Center | Nanobody conjugates (VHH) and their uses |
| US20240109954A1 (en) * | 2021-02-01 | 2024-04-04 | The General Hospital Corporation | Fc-enhanced antibodies for prevention and treatment of ebola virus infection |
| TW202246334A (zh) * | 2021-02-02 | 2022-12-01 | 美商美國禮來大藥廠 | Gitr拮抗劑及其使用方法 |
| WO2024017915A1 (en) | 2022-07-18 | 2024-01-25 | Ablynx N.V. | Cx3cr1-binding compounds, uses thereof and related methods |
| KR20250126016A (ko) | 2022-12-22 | 2025-08-22 | 치오메 바이오사이언스 가부시키가이샤 | 항인간 cx3cr1 항체 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| WO2001060406A1 (en) * | 2000-02-18 | 2001-08-23 | Millennium Pharmaceuticals, Inc. | Therapeutic methods that target fractalkine or cx3cr1 |
| EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20020192212A1 (en) * | 2001-03-19 | 2002-12-19 | Toshio Imai | Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| JP4123856B2 (ja) | 2001-07-31 | 2008-07-23 | 日油株式会社 | 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法 |
| US20050069962A1 (en) | 2001-10-12 | 2005-03-31 | Archer Robert M | Antibody complexes and methods for immunolabeling |
| AU2002364587A1 (en) | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1511850A4 (en) | 2002-06-10 | 2006-06-07 | Metabolex Inc | METHODS OF TREATING AND DIAGNOSING DIABETES USING MODULATORS OF CX3CR1 |
| WO2004041867A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders |
| WO2004060965A2 (en) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| CN1845938B (zh) | 2003-06-30 | 2010-05-26 | 杜门蒂斯有限公司 | 多肽 |
| WO2005103684A2 (en) | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1) |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| ES2641815T3 (es) | 2004-10-29 | 2017-11-14 | Eisai R&D Management Co., Ltd. | Tratamiento para enfermedades inflamatorias |
| WO2006122787A1 (en) | 2005-05-18 | 2006-11-23 | Ablynx Nv | Serum albumin binding proteins |
| CA2615460A1 (en) | 2005-08-08 | 2007-02-15 | Onconon, Llc | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
| KR20130108481A (ko) * | 2005-08-19 | 2013-10-02 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| CN101646689A (zh) * | 2006-09-08 | 2010-02-10 | 埃博灵克斯股份有限公司 | 具有长半衰期的血清清蛋白结合蛋白 |
| CA2671581A1 (en) | 2006-12-05 | 2008-06-12 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| CN101965362A (zh) | 2008-03-05 | 2011-02-02 | 埃博灵克斯股份有限公司 | 新型抗原结合二聚体-复合物及其制备方法和应用 |
| EP2268668A1 (en) | 2008-04-17 | 2011-01-05 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| AU2009254501B2 (en) | 2008-06-05 | 2014-07-31 | Ablynx N.V. | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
| WO2010070394A1 (en) | 2008-12-17 | 2010-06-24 | Universite Pierre Et Marie Curie-Paris Vi | Modulators of the cx3cr1 receptor and therapeutic uses thereof |
| WO2011042398A1 (en) * | 2009-10-09 | 2011-04-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them |
| WO2011044377A2 (en) | 2009-10-09 | 2011-04-14 | Cell Point, Llc | Chelator-targeting ligand conjugates for cardiovascular imaging |
| JP6076913B2 (ja) * | 2010-12-07 | 2017-02-08 | ドレクセル ユニバーシティ | 癌からの転移を阻害する方法 |
| AU2013226340B2 (en) | 2012-02-27 | 2017-06-22 | Ablynx N.V. | CX3CR1-binding polypeptides |
| WO2015026884A1 (en) | 2013-08-21 | 2015-02-26 | Boehringer Ingelheim International Gmbh | Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease |
-
2013
- 2013-02-25 AU AU2013226340A patent/AU2013226340B2/en active Active
- 2013-02-25 NZ NZ627260A patent/NZ627260A/en unknown
- 2013-02-25 IL IL291571A patent/IL291571B2/en unknown
- 2013-02-25 AP AP2014007791A patent/AP2014007791A0/xx unknown
- 2013-02-25 SG SG11201405283SA patent/SG11201405283SA/en unknown
- 2013-02-25 EA EA201400964A patent/EA028183B1/ru not_active IP Right Cessation
- 2013-02-25 PH PH1/2014/501912A patent/PH12014501912B1/en unknown
- 2013-02-25 PE PE2014001293A patent/PE20141859A1/es active IP Right Grant
- 2013-02-25 PH PH1/2021/553014A patent/PH12021553014A1/en unknown
- 2013-02-25 JP JP2014558920A patent/JP6101715B2/ja active Active
- 2013-02-25 CN CN202210946091.2A patent/CN115925938A/zh active Pending
- 2013-02-25 GE GEAP201313583A patent/GEP201706773B/en unknown
- 2013-02-25 CN CN201810147778.3A patent/CN108610421B/zh active Active
- 2013-02-25 WO PCT/US2013/027580 patent/WO2013130381A1/en not_active Ceased
- 2013-02-25 EP EP13709641.8A patent/EP2820046B1/en active Active
- 2013-02-25 MX MX2014009864A patent/MX349192B/es active IP Right Grant
- 2013-02-25 KR KR1020147023938A patent/KR102008136B1/ko active Active
- 2013-02-25 UA UAA201410430A patent/UA115781C2/uk unknown
- 2013-02-25 CN CN201380016996.9A patent/CN104245735B/zh active Active
- 2013-02-25 CA CA2862182A patent/CA2862182A1/en not_active Abandoned
- 2013-02-25 US US13/775,307 patent/US9035029B2/en active Active
- 2013-02-25 IN IN5756DEN2014 patent/IN2014DN05756A/en unknown
- 2013-02-25 IL IL311502A patent/IL311502A/en unknown
- 2013-02-25 MD MDA20140104A patent/MD4548C1/ro not_active IP Right Cessation
- 2013-02-25 EP EP22168124.0A patent/EP4050027A3/en active Pending
- 2013-02-26 TW TW102106771A patent/TWI598361B/zh active
- 2013-02-26 AR ARP130100585A patent/AR090158A1/es active IP Right Grant
- 2013-02-27 UY UY0001034644A patent/UY34644A/es unknown
-
2014
- 2014-07-09 ZA ZA2014/05021A patent/ZA201405021B/en unknown
- 2014-08-05 CL CL2014002072A patent/CL2014002072A1/es unknown
- 2014-08-07 IL IL234018A patent/IL234018B2/en unknown
- 2014-08-26 TN TNP2014000360A patent/TN2014000360A1/fr unknown
- 2014-09-25 EC ECIEPI201420402A patent/ECSP14020402A/es unknown
-
2015
- 2015-04-09 US US14/682,131 patent/US9458235B2/en active Active
-
2016
- 2016-08-22 US US15/242,639 patent/US9783612B2/en active Active
-
2017
- 2017-09-29 US US15/720,792 patent/US10385134B2/en active Active
-
2019
- 2019-07-09 US US16/505,773 patent/US11384151B2/en active Active
-
2022
- 2022-06-09 US US17/836,473 patent/US12221487B2/en active Active
-
2023
- 2023-09-19 ZA ZA2023/08846A patent/ZA202308846B/en unknown
- 2023-09-19 ZA ZA2023/08845A patent/ZA202308845B/en unknown